Jacobio Pharmaceuticals Group Co (HKSE:01167) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is Jacobio Pharmaceuticals Group Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Jacobio Pharmaceuticals Group Co is: No Data: Cannot be evaluated.

Competitive Comparison of Jacobio Pharmaceuticals Group Co's Risk Assessment

For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jacobio Pharmaceuticals Group Co's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Jacobio Pharmaceuticals Group Co (HKSE:01167) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Jacobio Pharmaceuticals Group Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Jacobio Pharmaceuticals Group Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Jacobio Pharmaceuticals Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

77V:Germany

Address

No. 88, Kechuang 6th Street, Building F2, Beijing Economic-Technological Development Area, Beijing, CHN

Website

https://www.jacobiopharma.com

Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology therapies.

Executives

Qiming Corporate Gp Vi, Ltd.	2201 Interest of corporation controlled by you
Qiming Venture Partners Vi, L.p.	2101 Beneficial owner
Qiming Gp Vi, L.p.	2201 Interest of corporation controlled by you
Wang Yinxiang	2501 Other
Wang Xiaojie	2307 Founder of a discretionary trust who can infl
Hu Yunyan	2501 Other
Hillhouse Investment Management, Ltd.	2102 Investment manager
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Hh Spr-iii Holdings Limited	2101 Beneficial owner
Shen Zhu	2501 Other
Ultimate Estate Limited	2201 Interest of corporation controlled by you
Treasure Partner International Limited	2501 Other
Gloryviewpharma Ltd	2501 Other
Honourpharma Ltd	2501 Other
Blesspharma Ltd	2501 Other

Jacobio Pharmaceuticals Group Co Headlines

No Headlines